- Home
- ARDX
ARDX
Ardelyx Inc.
as 05-20-2024 9:34am EST
$.
+$.
+.%
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FREMONT |
| Market Cap: | 1.8B | IPO Year: | 2014 |
| Target Price: | $12.81 | AVG Volume (30 days): | 5.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.16 - $10.13 | Next Earning Date: | 05-02-2024 |
| Revenue: | $159,110,000 | Revenue Growth: | 152.32% |
| Revenue Growth (this year): | 71.54% | Revenue Growth (next year): | 73.15% |
Share on Social Networks:
Stock Insider Trading Activity of Ardelyx Inc. (ARDX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| RAAB MICHAEL | ARDX | President & CEO | May 14 '24 | Sell | $7.99 | 3,000 | $23,970.00 | 1,307,933 | SEC Form 4 |
| Williams Laura A | ARDX | Chief Medical Officer | May 3 '24 | Sell | $8.35 | 39,949 | $333,574.15 | 370,189 | SEC Form 4 |
| GRAMMER ELIZABETH A | ARDX | See Remarks | May 3 '24 | Sell | $9.00 | 45,000 | $405,000.00 | 267,993 | SEC Form 4 |
| RAAB MICHAEL | ARDX | President & CEO | Apr 15 '24 | Sell | $7.06 | 7,500 | $52,923.75 | 1,310,933 | SEC Form 4 |
| RAAB MICHAEL | ARDX | President & CEO | Apr 1 '24 | Sell | $7.31 | 1,518 | $11,096.58 | 1,318,433 | SEC Form 4 |
| GRAMMER ELIZABETH A | ARDX | See Remarks | Mar 20 '24 | Sell | $7.73 | 86,000 | $664,977.80 | 312,993 | SEC Form 4 |
| Rosenbaum David P. | ARDX | Chief Development Officer | Feb 26 '24 | Sell | $9.20 | 5,183 | $47,683.60 | 175,936 | SEC Form 4 |
| Rodriguez Susan | ARDX | Chief Commercial Officer | Feb 20 '24 | Sell | $8.75 | 6,928 | $60,594.37 | 452,795 | SEC Form 4 |
| GRAMMER ELIZABETH A | ARDX | See Remarks | Feb 20 '24 | Sell | $8.75 | 4,432 | $38,763.60 | 398,993 | SEC Form 4 |
| Rosenbaum David P. | ARDX | Chief Development Officer | Feb 20 '24 | Sell | $8.75 | 5,017 | $43,880.19 | 378,985 | SEC Form 4 |
| Rosenbaum David P. | ARDX | Chief Development Officer | Feb 20 '24 | Sell | $8.75 | 2,294 | $20,064.01 | 181,119 | SEC Form 4 |
| Renz Justin A | ARDX | Chief Financial Officer | Feb 20 '24 | Sell | $8.75 | 5,341 | $46,713.99 | 304,835 | SEC Form 4 |
| RAAB MICHAEL | ARDX | President & CEO | Feb 20 '24 | Sell | $8.75 | 22,917 | $200,438.96 | 1,319,951 | SEC Form 4 |
| Felsch Robert Ora | ARDX | See Remarks | Feb 20 '24 | Sell | $8.75 | 2,352 | $20,571.30 | 184,834 | SEC Form 4 |
| Williams Laura A | ARDX | Chief Medical Officer | Feb 20 '24 | Sell | $8.75 | 4,803 | $42,008.48 | 380,138 | SEC Form 4 |
| Rosenbaum David P. | ARDX | Chief Development Officer | Feb 8 '24 | Sell | $9.18 | 15,344 | $140,845.64 | 384,002 | SEC Form 4 |
| Rosenbaum David P. | ARDX | Chief Development Officer | Dec 18 '23 | Sell | $6.07 | 5,675 | $34,447.25 | 316,596 | SEC Form 4 |
| Rosenbaum David P. | ARDX | Chief Development Officer | Dec 14 '23 | Sell | $5.55 | 7,000 | $38,850.00 | 322,271 | SEC Form 4 |
| Rosenbaum David P. | ARDX | Chief Development Officer | Nov 30 '23 | Sell | $4.50 | 3,000 | $13,500.00 | 359,543 | SEC Form 4 |
| Blanks Robert | ARDX | See Remarks | Nov 20 '23 | Sell | $4.36 | 2,835 | $12,366.84 | 260,453 | SEC Form 4 |
| RAAB MICHAEL | ARDX | President & CEO | Nov 20 '23 | Sell | $4.36 | 11,368 | $49,589.49 | 867,868 | SEC Form 4 |
| Renz Justin A | ARDX | Chief Financial Officer | Nov 20 '23 | Sell | $4.36 | 2,873 | $12,532.60 | 332,426 | SEC Form 4 |
| Felsch Robert Ora | ARDX | See Remarks | Nov 20 '23 | Sell | $4.36 | 1,044 | $4,554.14 | 117,066 | SEC Form 4 |
| Williams Laura A | ARDX | Chief Medical Officer | Nov 15 '23 | Sell | $4.00 | 25,000 | $99,997.50 | 266,839 | SEC Form 4 |
Latest Ardelyx Inc. News
ARDX Breaking Stock News: Dive into ARDX Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
GlobeNewswire
6 days ago
Ardelyx, Inc. Reports Employment Inducement Grants
MT Newswires
11 days ago
Ardelyx Insider Sold Shares Worth $2,522,217, According to a Recent SEC Filing
MT Newswires
11 days ago
Ardelyx Insider Sold Shares Worth $1,831,503, According to a Recent SEC Filing
MT Newswires
13 days ago
Ardelyx Insider Sold Shares Worth $333,574, According to a Recent SEC Filing
GlobeNewswire
13 days ago
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
Insider Monkey
16 days ago
Ardelyx, Inc. (NASDAQ:ARDX) Q1 2024 Earnings Call Transcript
Simply Wall St.
16 days ago